Pneumococcal pneumonia: Clinical features, diagnosis and management in HIV-infected and HIV noninfected patients

Current Opinion in Pulmonary Medicine

Volumn 15, Issue 3, 2009, Pages 236-242

  Madeddu, Giordano ^a   Fois, Alessandro Giuseppe ^a   Pirina, Pietro ^a   Mura, Maria Stella ^a  

^a UNIVERSITY OF SASSARI   (Italy)

Author keywords

Clinical features; Diagnosis; HIV; Management; Pneumococcal pneumonia

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; AZITHROMYCIN; BACTERIAL POLYSACCHARIDE; BETA LACTAM ANTIBIOTIC; CLARITHROMYCIN; DOXYCYCLINE; ERYTHROMYCIN; GEMIFLOXACIN; LEVOFLOXACIN; MACROLIDE; MOXIFLOXACIN; PNEUMOCOCCUS VACCINE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; ANTIINFECTIVE AGENT;

ADULT; ALCOHOL ABUSE; ANTIBIOTIC THERAPY; ANTIGEN DETECTION; BACTEREMIA; CD4 LYMPHOCYTE COUNT; CLINICAL FEATURE; COMMUNITY ACQUIRED PNEUMONIA; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; IMMUNOCOMPROMISED PATIENT; INTRAVENOUS DRUG ABUSE; MORTALITY; PHYSICAL EXAMINATION; PNEUMONIA SEVERITY INDEX; REVIEW; RISK FACTOR; SMOKING; STREPTOCOCCUS PNEUMONIA; STREPTOCOCCUS PNEUMONIAE; THORAX RADIOGRAPHY; URINE; VACCINATION; AIDS RELATED COMPLEX; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MICROBIOLOGY; PATHOGENICITY;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-BACTERIAL AGENTS; HIV INFECTIONS; HUMANS; PNEUMOCOCCAL VACCINES; PNEUMONIA, PNEUMOCOCCAL; STREPTOCOCCUS PNEUMONIAE;

EID: 67649171341     PISSN: 10705287     EISSN: 15316971     Source Type: Journal    
DOI: 10.1097/MCP.0b013e32832a09e0     Document Type: Review

References (51)

1. Lim WS, Macfarlane JT, Boswell TC, et al. Study of community acquired pneumonia aetiology (SCAPA) in adults admitted to hospital: implications for management guidelines. Thorax 2001; 56:296-301.
2. Woodhead MA, Macfarlane JT, McCracken JS, et al. Prospective study of the aetiology and outcome of pneumonia in the community. Lancet 1987; 1:671-674.
3. Kozak LJ, Owings MF, Hall MJ. National Hospital Discharge Survey: 2002 annual summary with detailed diagnosis and procedure data. National Center for Health Statistics. Vital Health Stat 2005;(158):13. http://www.cdc.gov/ nchs/data/series/sr-13/sr13-158.pdf.
4. Bartlett JG, Mundy LM. Community-acquired pneumonia. N Engl J Med 1995; 333:1618-1624.
5. Brown PD, Lerner SA. Community-acquired pneumonia. Lancet 1998; 352:1295e302.
6. Fang G, Fine M, Orleff J, et al. New and emerging etiologies for community acquired pneumonia with implications for therapy. Medicine 1990; 69:307-316.
7. Mundy L, Aurwaeter P, Oldack D, et al. Community-acquired pneumonia. Impact of immune status. Am J Respir Crit Care Med 1995; 152:1309-1315.
8. File TM, Garau J, Blasi F, et al. Guidelines for empiric antimicrobial prescribing in community-acquired pneumonia. Chest 2004; 125:1913-1919.
9. Thibodeau KP, Viera AJ. Atypical pathogens and challenges in communityacquired pneumonia. Am Fam Phys 2004; 69:1699-1706.
10. Ginesu F, Pirina P, Deiola G, et al. Etiology and therapy of communityacquired pneumonia. J Chemother 1997; 9:285-292.
11. Marrie T, Durant H, Yates L. Community-acquired pneumonia requiring hospitalization: 5 year prospective study. Rev Infect Dis 1989; 11:586-599.
12. Hirshtick RE, Glassroth J, Jordan MC, et al. Bacterial pneumonia in persons infected with the human immunodeficiency virus. Pulmonary complications of HIV Infection Study Group. N Engl J Med 1995; 333:845-851.
13. Saindou M, Chidiac C, Miailhes P, et al. Pneumococcal pneumonia in HIVinfected patients by antiretroviral therapy periods. HIV Med 2008; 9:203-207.
14. Talbot TR, Hartert TV, Mitchel E, et al. Asthma as a risk factor for invasive pneumococcal disease. N Engl J Med 2005; 352:2082-2090.
15. Juhn YJ, Kita H, Yawn BP, Boyce TG, et al. Increased risk of serious pneumococcal disease in patients with asthma. J Allergy Clin Immunol 2008; 122:719-723.
16. Metlay JP, Schults R, Li YH, et al. Influence of age on symptoms at presentation in patients with community-acquired pneumonia. Arch Intern Med 1997; 157:1453-1459.
17. Janssens JP, Krause KH. Pneumonia in the very old. Lancet Infect Dis 2004; 4:112-124.
18. Heffron R. Symptoms of lobar pneumonia. In: Pneumonia with special reference to pneumococcus lobar pneumonia. Cambridge, MA: Harvard University Press; 1939. p. 501.
19. Vines-Douglas G. Diagnosing and treating CAP in immunocompetent adults. JAAPA 2008; 21:26-30.
20. Justice AC, Lasky E, McGinnis KA, et al. Medical disease and alcohol use among veterans with human immunodeficiency infection: a comparison of disease measurement strategies. Med Care 2006; 44:S52-S60.
21. Feldman C, Klugman KP, Yu VL, et al., International Pneumococcal Study Group. Bacteraemic pneumococcal pneumonia: impact of HIV on clinical presentation and outcome. J Infect 2007; 55:125-135.
22. Madeddu G, Porqueddu EM, Cambosu F, et al. Bacterial community acquired pneumonia in HIV-infected inpatients in the highly active antiretroviral therapy era. Infection 2008; 36:231-236.
23. Jover F, Cuadrado JM, Andreu L, et al. A comparative study of bacteremic and nonbacteremic pneumococcal pneumonia. Eur J Intern Med 2008; 19:15-21.
24. Hoban DJ, Doern GV, Fluit AC, et al. Worldwide prevalence of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the SENTRY Antimicrobial Surveillance Program, 1997-1999. Clin Infect Dis 2001; 15:32 (Suppl 2):S81-S93.
25. Beekmann SE, Heilmann KP, Richter SS, et al. Antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis and group A b-haemolytic streptococci in 2002-2003, Results of the multinational GRASP Surveillance Program. Int J Antimicrob Agents 2005; 25:148-156.
26. Buie KA, Klugman KP, von Gottberg A, et al. Gender as a risk factor for both antibiotic resistance and infection with pediatric serogroups/serotypes in HIVinfected and -uninfected adults with pneumococcal bacteremia. J Infect Dis 2004; 189:1996-2020.
27. Pemba L, Charalambous S, von Gottberg A, et al. Impact of cotrimoxazole on nonsusceptibility to antibiotics in Streptococcus pneumoniae carriage isolates among HIV-infected mineworkers in South Africa. J Infect 2008; 56:171-178.
28. Lujan M, Gallego M, Fontanals D, et al. Prospective observational study of bacteremic pneumococcal pneumonia: effect of discordant therapy on mortality. Crit Care Med 2004; 32:625-631.
29. Daneman N, McGeer A, Green K, Low DE. Macrolide resistance in bacteremic pneumococcal disease: implications for patient management. Clin Infect Dis 2006; 43:432-438.
30. Niederman MS, Mandell LA, Azueto A, et al. Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med 2001; 16:590-598.
31. Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007; 44 (Suppl 2):S27.
32. Boulware DR, Daley CL, Merrifield C, et al. Rapid diagnosis of pneumococcal pneumonia among HIV-infected adults with urine antigen detection. J Infect 2007; 55:300-309.
33. Doḿnguez J, Gally N, Blanco S, et al. Detection of Streptococcus pneumoniae antigen by a rapid immunochromatographic assay in urine samples. Chest 2001; 119:243-249.
34. Marcos MA, Jimenez de Anta MT, de la Bellacasa JP, et al. Rapid urinary antigen test for diagnosis of pneumococcal community-acquired pneumonia in adults. Eur Respir J 2003; 21:209-214.
35. Carbonara S, Stano F, Scotto G, et al. The correct approach to communityacquired pneumonia in immunocompetent adults: review of current guidelines. New Microbiol 2008; 31:1-18.
36. British Thoracic Society Standards of Care Committee. BTS Guidelines for the Management of Community Acquired Pneumonia in Adults. Thorax 2001; 56 (Suppl 4):iv1-iv64.
37. Mandell LA, Marrie TJ, Grossman RF, et al. Summary of Canadian guidelines for the initial management of community-acquired pneumoniae: an evidencebased update by Canadian Infectious Disease Society and Canadian Thoracic Society. The Canadian Community-Acquired Pneumonia Working Group. Clin Infect Dis 2000; 31:383-421.
38. Bartlett JG, Dowell SF, Mandell LA, et al. Practice guidelines for the management of community-acquired pneumonia in adults. Infectious Disease Society of America. Clin Infect Dis 2000; 31:347-382.
39. European Study on community-acquired pneumonia committee. Guidelines for management of adults community-acquired lower respiratory tract infections. Eur Respir J 1998; 11:986-991.
40. American Thoracic Society. Guidelines for the initial management of adults with community-acquired pneumonia: diagnosis, assessment of severity, and initial antimicrobial therapy. Am Rev Respir Dis 1993; 148:1418-1426.
41. British Thoracic Society. Guidelines for the management of communityacquired pneumonia in adults admitted to hospital. Br Hosp Med 1993; 49:146-350.
42. Fine MJ, Auble TE, Yealy DM, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 1997; 336:243-250.
43. Curran A, Falcó V, Crespo M, et al. Bacterial pneumonia in HIV-infected patients: use of the pneumonia severity index and impact of current management on incidence, aetiology and outcome. HIV Med 2008; 9:609-615.
44. Lexau CA. The changing epidemiology of pneumococcal pulmonary disease in the era of the heptavalent vaccine. Curr Infect Dis Resp 2008; 10:229-235.
45. French N, Nakiyingi J, Carpenter LM, et al. 23-valent pneumococcal polysaccharide vaccine in HIV-1-infected Ugandan adults: double-blind, randomized and placebo controlled trial. Lancet 2000; 355:2016-2111.
46. Rodriguez-Barradas MC, Musher DM, Lahart C, et al. Antibody to capsular polysaccharides of Streptococcus pneumoniae after vaccination of human immunodeficiency virus-infected subjects with 23-valent pneumococcal vaccine. J Infect Dis 1992; 165:553-556.
47. Loeliger AF, Rijkers GT, Aerts P, et al. Deficient antipneumococcal polysaccharide responses in HIV-seropositive patients. FEMS Immunol Med Microbiol 1995; 12:33-41.
48. Sybil AT, Wallace MR, Rubins JB, et al. Reimmunization with 23-valent pneumococcal vaccine for patients infected with human immunodeficiency virus type-1: clinical, immunologic, and virologic responses. Clin Infect Dis 2002; 34:813-821.
49. Falcó V, Jordano Q, Cruz MJ, et al. Serological response to pneumococcal vaccination in HAART-treated HIV-infected patients: one year follow-up study. Vaccine 2006; 24:2567-2574.
50. Penaranda M, Falcó V, Payeras A, et al. Effectiveness of polysaccharide pneumococcal vaccine in HIV-infected patients: a case-control study. Clin Infect Dis 2007; 45:82-87.
51. Rodriguez-Barradas MC, Goulet J, Brown S, et al. Impact of pneumococcal vaccination on the incidence of pneumonia by HIV infection status among patients enrolled in the Veterans Aging Cohort 5-Site Study. Clin Infect Dis 2008; 46:1093-1100.